EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia.

Marius BillAparna PathmanathanMalith KarunasiriChangxian ShenMatthew H BurkeParvathi RanganathanDimitrios PapaioannouNina C ZitzerKatiri SnyderAllison LaRoccoAllison E WalkerZachary J BrannanAnsel P Nalin Aharon G FreudMikhail M DikovXiaoli ZhangClara D BloomfieldRamiro GarzonAdrienne M Dorrance

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our data demonstrate that EGFL7 contributes to NOTCH silencing in AML by antagonizing canonical NOTCH ligand binding. Reactivation of NOTCH signaling in vivo using anti-EGFL7 results in prolonged survival of leukemic mice, supporting the use of EGFL7 as a novel therapeutic target in AML.

Keyphrases

acute myeloid leukemia
cell proliferation
allogeneic hematopoietic stem cell transplantation
electronic health record
type diabetes
high fat diet induced
machine learning
insulin resistance
artificial intelligence